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Abstract
Background: Several medications commonly used to treat generalized anxiety disorder (GAD)
have been designated "potentially inappropriate" for use in patients aged ≥65 years because their
risks may outweigh their potential benefits. The actual extent of use of these agents in clinical
practice is unknown, however.
Methods: Using a database with information from encounters with general practitioners (GP) in
Germany, we identified all patients, aged ≥65 years, with any GP office visits or dispensed
prescriptions with a diagnosis of GAD (ICD-10 diagnosis code F41.1) between 10/1/2003 and 9/30/
2004 ("GAD patients"). Among GAD-related medications (including benzodiazepines, tricyclic
antidepressants [TCAs], selective serotonin reuptake inhibitors, venlafaxine, hydroxyzine,
buspirone, pregabalin, and trifluoperazine), long-acting benzodiazepines, selected short-acting
benzodiazepines at relatively high dosages, selected TCAs, and hydroxyzine were designated
"potentially inappropriate" for use in patients aged ≥ 65 years, based on published criteria.
Results: A total of 975 elderly patients with GAD were identified. Mean age was 75 years, and 72%
were women; 29% had diagnoses of comorbid depression. Forty percent of study subjects received
potentially inappropriate agents – most commonly, bromazepam (10% of all subjects), diazepam
(9%), doxepin (7%), amitriptyline (5%), and lorazepam (5%). Twenty-three percent of study subjects
received long-acting benzodiazepines, 10% received short-acting benzodiazepines at relatively high
doses, and 12% received TCAs designated as potentially inappropriate.
Conclusion: GPs in Germany often prescribe medications that have been designated as potentially
inappropriate to their elderly patients with GAD – especially those with comorbid depressive
disorders. Further research is needed to ascertain whether there are specific subgoups of elderly
patients with GAD for whom the benefits of these medications outweigh their risks.
Background
Generalized anxiety disorder (GAD) is a chronic condi-
tion that is characterized by persistent worry or anxiety
that occurs more days than not over a period of at least six
months [1]. The condition is frequently difficult to diag-
nose because of the variety of clinical presentations and
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the common occurrence of comorbid medical or other
psychiatric conditions. Lifetime prevalence has been esti-
mated to be between 4% and 6% [2]; the disease is more
common among women than men. GAD is the most com-
mon anxiety disorder among patients presenting to pri-
mary care physicians [3,4].
Several different types of medications are often used to
treat GAD – specifically, benzodiazepines (e.g., flu-
razepam, diazepam, chlordiazepoxide), buspirone, tricy-
clic antidepressants (TCAs) (e.g., amitriptyline,
imipramine, doxepin, opipramol), selective serotonin
reuptake inhibitors (SSRIs) (e.g., paroxetine. escitalo-
pram), and venlafaxine (a selective serotonin and nore-
pinephrine reuptake inhibitor) [5-7]. Among these
available therapies, benzodiazepines have long been the
mainstay of pharmacologic treatment for GAD. While
effective, benzodiazepines are associated with excessive
sedation and motor impairment [8]; their long-term use is
also associated with a risk of physical dependence as well
as withdrawal when therapy is discontinued [6]. In one
study comparing 4554 persons prescribed benzodi-
azepines with 13,662 persons receiving other (i.e., non-
benzodiazepine) medications who were matched on age,
sex, and calendar month in which therapy was initiated,
Oster and colleagues found that patients in the former
group had a 15% higher risk of an accident-related medi-
cal event; those who filled three or more prescriptions for
benzodiazepines had a 30% higher risk compared with
those who filled only one such prescription [9].
An expert panel convened by Beers in 1991 developed
explicit criteria for identifying medication use among
nursing home residents that was potentially inappropriate
[10]. Recognizing that these criteria were developed spe-
cifically for a nursing home population, Beers convened
another expert panel in 1997 to develop criteria applica-
ble to the entire population of older persons (≥65 years);
the resulting criteria designated some of the drugs used to
treat GAD (benzodiazepines, amitriptyline, doxepin) as
potentially inappropriate for use in persons aged ≥ 65
years [11]. The panel compiled its list of potentially inap-
propriate medications without regard to diagnosis or
place of residence, and sought to include only those
agents whose ". . . potential for adverse outcomes is
greater than the potential for benefit" [11].
While well-known and extensively cited, the Beers' criteria
have been criticized as not providing a sufficient basis for
identifying inappropriate prescribing, as they are not indi-
cation-specific [12]. A subsequent expert panel convened
by Zhan et al. classified 33 medications on the Beers' list
alternatively as always to be avoided, rarely appropriate,
and appropriate for some indications [13]. Among drugs
that are sometimes used to treat GAD, flurazepam was
designated as "always to be avoided"; chlordiazepoxide
and diazepam were designated as "rarely appropriate";
and amitriptyline and doxepin, "appropriate for some
indications".
In their update of the Beers' criteria, Fick et al. designated
flurazepam, amitriptyline, chlordiazepoxide, doxepin,
and anything other than low doses of short-acting benzo-
diazepines (e.g., >3 mg lorazepam) as potentially inap-
propriate for use in older patients; adverse outcomes for
all such medications were deemed by the authors to be of
high (versus low) severity [14].
Despite their limitations, the 1997 Beers' criteria have
been widely used by researchers to identify potential med-
ication risks [13,15-19]. An epidemiologic study of non-
institutionalized persons who participated in the 1987 US
National Medical Expenditure Survey reported that 23.5%
of those aged ≥65 years received at least one of the 20
medications on the Beers' list [20]. Zhan et al. applied
their revised list to persons participating in the 1996 US
Medical Expenditure Panel Survey and reported that
21.3% received drugs that were potentially – albeit not
necessarily – inappropriate, 2.6% received medications
that should always be avoided, and 9.1% received drugs
that were rarely appropriate; 3.4% of those aged >65 years
had received amitriptyline [13].
Recently, an examination of 2707 older home-care
patients from eight countries across Europe found that
19.8% received at least one medication designated as
potentially inappropriate; in multivariate analysis, use of
anxiolytics was associated with a twofold increase in the
likelihood of receiving potentially inappropriate medica-
tions [21]. Some of the most commonly used, potentially
inappropriate medications in this study were benzodi-
azepines (diazepam [3.1% of patients received such ther-
apy] and chlordiazepoxide [0.6%]) and tricyclic
antidepressants (amitriptyline [1.4%]) – agents often
used for the treatment of GAD.
Although older adults with GAD would appear to often
receive potentially inappropriate medications, the actual
extent of such use in clinical practice is unknown. Moreo-
ver, the generalizability of earlier findings – based largely
on US data – to other countries is unknown. In this study,
we examine the magnitude of exposure of patients aged
≥65 years with GAD to potentially inappropriate medica-
tions in Germany, a large European country in which
observed patterns of treatment of GAD may possibly be
reflective of those throughout Europe.
Methods
Data were obtained from the IMS MediPlus – Disease
Analyzer database; a detailed description of the databaseBMC Geriatrics 2009, 9:31 http://www.biomedcentral.com/1471-2318/9/31
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and its research capabilities may be found elsewhere [22].
The database is longitudinal in nature, and provides
patient-level information on consultations, diagnoses,
and treatments from over 900 GP practices throughout
Germany, comprising more than 4.2 million patient
records and 75 million prescriptions over a 10-year
period. The database is compiled by sampling practices
throughout Germany, and is designed to be representative
of the general population in Germany. All patient identi-
fiers in the database are fully encrypted.
Information in the IMS MediPlus – Disease Analyzer data-
base includes date of service, diagnoses (in ICD-10 for-
mat), actions taken (e.g., referrals to other providers [i.e.,
specialists], dispensing of sick notes [physician-excused
absences from work]), and medications dispensed,
including the dispensing date, the quantity dispensed, the
number of days of therapy supplied, and the associated
diagnosis (available for about 60% of all prescription
records). Selected demographic information is also avail-
able, including patient age and gender. All patient-level
data can be arrayed chronologically to provide a detailed,
longitudinal profile of all medical and pharmacy services
rendered by participating GPs. Because this study was ret-
rospective in nature, used completely anonymized data,
and did not involve patient contact, institutional review
board (IRB) approval was not sought. The database for
this study encompassed the period, October 1, 2003
through September 30, 2004 ("study period").
The study sample consisted of all patients with any GP
office visits or dispensed prescriptions with a diagnosis of
GAD (ICD-10 diagnosis code F41.1) during the study
period. Persons aged <65 years as of their first-noted
encounter for GAD were excluded from the study sample.
All GP encounters were then compiled for all subjects over
the one-year period of study.
The prevalence of a number of medically attended comor-
bidities (i.e., noted by GPs during office or clinic visits)
was examined for patients in the study sample, including:
(1) neoplasms; (2) anemia and other blood antibody dis-
orders; (3) diabetes; (4) circulatory system disorders; (5)
respiratory system disorders; (6) eye, nose, and throat dis-
orders; (7) digestive system disorders; (8) painful neuro-
pathic disorders (e.g., diabetic peripheral neuropathy,
post-herpetic neuralgia, causalgia, neuropathic back
pain); (9) musculoskeletal system disorders; (10) symp-
tom, signs, ill-defined conditions; (11) somatoform dis-
orders; (12) neurasthenia; (13) substance use disorders;
and (14) sleep disorders. Patients were deemed to have
these conditions if they had any encounters during the
study period with the corresponding diagnosis code(s).
The numbers of patients receiving various medications
often used to treat GAD ("GAD-related medications")
were tabulated. Medications (and corresponding dosages,
if relevant [see below]) were deemed "potentially inap-
propriate" based on their inclusion in Beers' 1997 criteria
and/or in subsequent updates to these criteria [11,13,14].
Medication regimens designated as potentially inappro-
priate were as follows: (1) alprazolam (>2 mg daily); (2)
amitriptyline; (3) chlorazepate; (4) chlordiazepoxide; (5)
diazepam; (6) doxepin; (7) flurazepam; (8) halazepam;
(9) lorazepam (>3 mg daily); (10) oxazepam (>60 mg
daily); (11) temazepam (>15 mg daily); (12) triazolam
(>0.25 mg daily); and (13) zolpidem (>5 mg daily) [Table
1]. Daily dose was calculated using information in the
database; in instances where such information was miss-
ing, daily dose was assumed equivalent to the modal
value from all other prescriptions for the same product
with non-missing values.
Medication receipt was ascertained for the overall study
sample, as well as within strata defined on the basis of age,
sex, and selected comorbidities (e.g., depression, neo-
plasms, respiratory disorders). The statistical significance
of differences within strata was ascertained using chi-
square tests and Fisher's exact tests, as appropriate. All
analyses were conducted using PC-SAS® v.9.1 [23].
Results
The study sample consisted of 975 patients, aged ≥65
years, with diagnoses of GAD; mean (± SD) age was 75.0
(± 7.3) years, and 71.6% were women [Table 2]. Twenty-
four percent of study subjects had at least one encounter
during the study period at which a diagnosis of another
anxiety disorder was noted; 29.2% had at least one
encounter resulting in a diagnosis of depression. The prev-
alence of other medically attended comorbidities was
high, including circulatory disorders (87.5%), digestive
disorders (56.0%), respiratory disorders (42.5%), muscu-
loskeletal disorders (69.5%), painful neuropathies
(28.8%), and sleep disorders (24.7%). Ninety-eight per-
cent of patients had at least one comorbidity, and 87.0%
had three or more.
A total of 607 study subjects (62.3%) had received one or
more GAD-related medications (both those deemed
potentially inappropriate and all others) from their GPs –
most commonly, benzodiazepines (43.7%), including
both short-acting (24.8%) and long-acting (23.1%) for-
mulations, and TCAs (25.6%) [Table 3]. Nine percent of
patients received SSRIs, and 0.9% received venlafaxine.
About forty percent of study subjects – or two-thirds of
patients (64.6%) with evidence of receipt of GAD-related
medications – were dispensed at least one therapy consid-
ered potentially inappropriate for use in the elderly. Ten
percent of patients received short-acting benzodiazepines
at dosages that rendered their use potentially inappropri-
ate, 23.1% received long-acting benzodiazepines, andBMC Geriatrics 2009, 9:31 http://www.biomedcentral.com/1471-2318/9/31
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12.2% received amitriptyline or doxepin (primarily dox-
epin).
Receipt of potentially inappropriate therapy did not differ
by age (39.1% for patients aged 65–74 years vs 41.5% for
patients aged ≥75 years; p = 0.45) or gender (41.1% of
men vs 37.9% of women; p = 0.36). Patients with comor-
bid depression were more likely to receive potentially
inappropriate therapy (51.6% vs 35.5% for those without
comorbid depression; p < 0.01), as were those with diges-
tive system disorders (43.0% vs 36.6% for those without
these disorders; p = 0.04), and those with sleep disorders
(62.2% vs 33.0% for those without these disorders; p <
0.01); receipt of these therapies did not differ significantly
for patients with versus without any of the other selected
comorbidities.
Table 1: Medications for treatment of generalized anxiety disorder
Medication Type Comment
Benzodiazepines
Short-acting
Alprazolam >2 mg/d deemed potentially inappropriate
Bromazepam
Lorazepam >3 mg/d deemed potentially inappropriate
Lormetazepam
Nitrazepam
Oxazepam >60 mg/d deemed potentially inappropriate
Temazepam >15 mg/d deemed potentially inappropriate
Tetrazepam
Triazolam >0.25 mg/d deemed potentially inappropriate
Zolpidem >5 mg/d deemed potentially inappropriate
Long-acting
Chlordiazepoxide All long-acting benzodiazepines deemed potentially inappropriate
Chlorazepate All long-acting benzodiazepines deemed potentially inappropriate
Clobazam All long-acting benzodiazepines deemed potentially inappropriate
Clonazepam All long-acting benzodiazepines deemed potentially inappropriate
Diazepam All long-acting benzodiazepines deemed potentially inappropriate
Flunitrazepam All long-acting benzodiazepines deemed potentially inappropriate
Flurazepam All long-acting benzodiazepines deemed potentially inappropriate
Halazepam All long-acting benzodiazepines deemed potentially inappropriate
Medazepam All long-acting benzodiazepines deemed potentially inappropriate
Nordazepam All long-acting benzodiazepines deemed potentially inappropriate
Prezepam All long-acting benzodiazepines deemed potentially inappropriate
Tricyclic antidepressants
Amitriptyline Deemed potentially inappropriate
Amitriptylinoxide
Clomipramine
Dibenzepin
Desipramine
Doxepin Deemed potentially inappropriate
Imipramine
Maprotiline
Nortiptyline
Opipramol
Trimipramine
Selective serotonin reuptake inhibitor
Escitalopram
Citalopram
Fluoxetine
Fluvoxamine
Paroxetine
Sertraline
Venlafaxine
Hydroxyzine Deemed potentially inappropriate
Buspirone
Pregabalin
TrifluoperazineBMC Geriatrics 2009, 9:31 http://www.biomedcentral.com/1471-2318/9/31
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Discussion
GAD can be difficult to treat, and several different medica-
tions – including benzodiazepines, buspirone, TCAs, and
SSRIs – are recommended for use in these patients [5-7].
Although these therapies are often of benefit, they also
can confer significant risks in older adults. Because of
these risks, some of these drugs have been designated
potentially inappropriate for use in persons aged 65 years
or older.
Using the 1997 Beers criteria [11] and subsequent updates
[13,14], we found that four out of every 10 patients – and
two out of every three of those who received any GAD-
related therapy – received medications that have been des-
ignated as potentially inappropriate for use among per-
sons aged 65 years and older. Notably, use of these
medications did not differ between the "young" old ver-
sus the "old" old (i.e., aged 65–74 years vs ≥ 75 years).
Benzodiazepines have long been the mainstay of pharma-
cologic treatment for GAD, and they were the medication
most commonly dispensed among subjects in our study:
44% of patients in our study received these agents. Para-
doxically, they also comprise the majority of agents
deemed potentially inappropriate for use in the elderly,
due in part to an increased risk of falls, hip fractures, drug-
induced disorders of cognition, and motor vehicle acci-
dents [9,24-27]. We note that GPs dispensed short-acting
benzodiazepines at daily doses deemed potentially inap-
propriate to 10% of study subjects; they also dispensed
long-acting benzodiazepines – which are deemed poten-
tially inappropriate in older patients regardless of daily
dose – to 31% of patients. About one in 10 patients in our
study received TCAs deemed potentially inappropriate –
either amitriptyline or doxepin – despite the fact that sev-
eral other TCAs (e.g., nortriptyline) are available with sim-
ilar efficacy that are better tolerated by older patients. We
are unaware of any other study of potentially inappropri-
ate prescribing in patients (of any age) with GAD. Com-
pared with rates of potentially inappropriate prescribing
reported among the elderly in general [13,16-21,28], the
rates we report are considerably higher. This finding is
consistent, however, with the fact that many of the medi-
cations that have been designated by some experts as
potentially inappropriate in the elderly are also com-
monly recommended by other experts to treat GAD.
As people age, their ability to metabolize drugs decreases,
and receptor sensitivity to the effects of pharmacotherapy
changes [29,30]. Unfortunately, older adults are often
underrepresented in randomized controlled trials [15], an
important source of information for prescribers. Conse-
quently, physicians may sometimes prescribe therapies on
presumptions of efficacy and safety based on clinical trial
results that are not necessarily generalizable to persons of
advanced age. This may explain why we found that so
many patients with GAD received medications that were
potentially inappropriate. Inappropriate prescribing also
may result from the use of inappropriate doses of other-
wise age-appropriate medications and/or not prescribing
medications that may be of benefit (e.g., not prescribing
GAD-related therapies for patients with this condition)
[31]. Accordingly, our findings probably underestimate
Table 2: Demographic and clinical characteristics of study 
subjects (N = 975)*
Characteristic
Age, years
65–74 507 (52.0)
75–84 365 (37.4)
≥85 103 (10.6)
Mean (SD) 75.0 (7.3)
Females 698 (71.6)
Males 277 (28.4)
Comorbid conditions
Anxiety disorders
Panic disorder 17 (1.7)
OCD 2 (0.2)
PTSD 0 (0.0)
Phobias
Social phobia 0 (0.0)
Agoraphobia 0 (0.0)
All other phobias 10 (1.0)
Any phobia 10 (1.0)
Other anxiety disorders 215 (22.1)
Any anxiety disorder (other than GAD) 237 (24.3)
Depression disorders
Dysthymic disorder 10 (1.0)
Adjustment disorder with depression 4 (0.4)
Bipolar depression 1 (0.1)
MDD 36 (3.7)
Unspecified depression 256 (26.3)
Any depression 285 (29.2)
Neoplasms 158 (16.2)
Anemia and other blood/antibody disorders 136 (13.9)
Diabetes 269 (27.6)
Circulatory system disorders 853 (87.5)
Respiratory system disorders 414 (42.5)
Eyes, nose, and throat 262 (26.9)
Digestive system disorders 546 (56.0)
Painful neuropathic disorders 281 (28.8)
Musculoskeletal system disorders 679 (69.6)
Symptoms, signs, ill-defined conditions 610 (62.6)
Somatoform disorders 130 (13.3)
Neurasthenia 39 (4.0)
Substance use disorders 30 (3.1)
Sleep disorders 241 (24.7)
Number of comorbidities
0 17 (1.7)
1 44 (4.5)
2 66 (6.8)
≥3 848 (87.0)
*Unless otherwise indicated, all values represent number (%)
GAD: Generalized anxiety disorder; OCD: Obsessive-compulsive 
disorder; PTSD: Post-traumatic stress disorder; MDD: Major 
depressive disorderBMC Geriatrics 2009, 9:31 http://www.biomedcentral.com/1471-2318/9/31
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Table 3: Numbers of study subjects receiving potentially inappropriate medications for treatment of GAD*
Medication Potentially Inappropriate Possibly Appropriate Total
Benzodiazepines
Short-acting
Alprazolam1 0 (0.0) 29 (3.0) 29 (3.0)
Lorazepam2 50 (5.1) 21 (2.2) 71 (7.3)
Lormetazepam 14 (1.4) 0 (0.0) 14 (1.4)
Oxazepam3 0 (0.0) 88 (9.0) 88 (9.0)
Temazepam4 8 (0.8) 0 (0.0) 8 (0.8)
Tetrazepam 0 (0.0) 29 (3.0) 29 (3.0)
Triazolam5 0 (0.0) 1 (0.1) 1 (0.1)
Zolpidem6 32 (3.3) 3 (0.3) 34 (3.5)
Any of above 97 (9.9) 162 (16.6) 242 (24.8)
Long-acting**
Chlordiazepoxide 6 (0.6) --- 6 (0.6)
Chlorazepate 11 (1.1) --- 11 (1.1)
Clobazam 2 (0.2) --- 2 (0.2)
Clonazepam 3 (0.3) --- 3 (0.3)
Diazepam 91 (9.3) --- 91 (9.3)
Flunitrazepam 7 (0.7) --- 7 (0.7)
Flurazepam 6 (0.6) --- 6 (0.6)
Halazepam 0 (0.0) --- 0 (0.0)
Medazepam 5 (0.5) --- 5 (0.5)
Nordazepam 2 (0.2) --- 2 (0.2)
Prezepam 0 (0.0) --- 0 (0.0)
Bromazepam 93 (9.5) --- 93 (9.5)
Nitrazepam 14 (1.4) --- 14 (1.4)
Midazolam 0 (0.0) --- 0 (0.0)
Any of above 225 (23.1) --- 225 (23.1)
Any of above 298 (30.6) 162 (16.6) 426 (43.7)
Tricyclic antidepressants
Amitriptyline 52 (5.3) --- 52 (5.3)
Amitriptylinoxide 0 (0.0) 3 (0.3) 3 (0.3)
Clomipramine 0 (0.0) 4 (0.4) 4 (0.4)
Dibenzepin 0 (0.0) 3 (0.3) 3 (0.3)
Desipramine 0 (0.0) 0 (0.0) 0 (0.0)
Doxepin 70 (7.2) --- 70 (7.2)
Imipramine 0 (0.0) 0 (0.0) 0 (0.0)
Maprotiline 0 (0.0) 4 (0.4) 4 (0.4)
Nortriptyline 0 (0.0) 0 (0.0) 0 (0.0)
Opipramol 0 (0.0) 105 (10.8) 105 (10.8)
Trimipramine 0 (0.0) 29 (3.0) 29 (3.0)
Any of above 119 (12.2) 142 (14.6) 250 (25.6)
Selective serotonin reuptake inhibitors
Escitalopram 0 (0.0) 7 (0.7) 7 (0.7)
Citalopram 0 (0.0) 40 (4.1) 40 (4.1)
Fluoxetine 11 (1.1) 0 (0.0) 11 (1.1)
Fluvoxamine 0 (0.0) 3 (0.3) 3 (0.3)
Paroxetine 0 (0.0) 16 (1.6) 16 (1.6)
Sertraline 0 (0.0) 13 (1.3) 13 (1.3)
Any of above 11 (1.1) 77 (7.9) 86 (8.8)
Venlafaxine 0 (0.0) 9 (0.9) 9 (0.9)
Hydroxyzine 4 (0.4) --- 4 (0.4)
Buspirone 0 (0.0) 5 (0.5) 5 (0.5)
Pregabalin 0 (0.0) 0 (0.0) 0 (0.0)
Trifluoperazine 0 (0.0) 0 (0.0) 0 (0.0)
Any of above 392 (40.2) 345 (35.4) 607 (62.3)
*All values are number of patients (%); dose calculated using all values found in database
**Any use of long-acting benzodiazepines deemed potentially inappropriate
1Dose >2 mg/d deemed potentially inappropriate
2Dose >3 mg/d deemed potentially inappropriate
3Dose >60 mg/d deemed potentially inappropriate
4Dose >15 mg/d deemed potentially inappropriate
5Dose > 0.25 mg/d deemed potentially inappropriate
6Dose >5 mg/d deemed potentially inappropriate
GAD: Generalized anxiety disorderBMC Geriatrics 2009, 9:31 http://www.biomedcentral.com/1471-2318/9/31
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the magnitude of potentially inappropriate prescribing in
Germany among older patients with GAD. Further study
is needed to ascertain the extent to which these other
aspects of potentially inappropriate prescribing are evi-
dent in this patient population.
The clinical implication of our findings appears to be that
benzodiazepines, amitriptyline, and doxepin are being
overprescribed in Germany among elderly patients with
GAD, especially among those with comorbid depression
and/or sleep disorders. A major limitation of our study,
however, is that we cannot assess the actual extent to
which prescribing was truly clinically inappropriate. The
treatment of GAD in the elderly is clinically complex and
presents many challenges. Since we did not employ a
"therapeutic timeline" as part of our research design,
patients could have received potentially inappropriate
agents either as initial treatment or following failure of
safer, more appropriate agents. To the extent that the latter
occurred, providers may have known about the risks asso-
ciated with these medications and nonetheless used them
only after a careful balancing of these risks against their
potential benefits in patients with severe symptoms [29].
Further study is needed to clarify the extent of truly clini-
cally inappropriate prescribing.
A second limitation of our study is that the list of poten-
tially inappropriate agents may be too rigid. For example,
while Beers classified amitriptyline as potentially inappro-
priate, Zhan et al. [13] deemed the use of low doses of this
agent as appropriate in older adults in some instances,
such as for the treatment of neuropathic pain. We note,
however, that the Beers criteria are not disease-specific;
these agents are deemed potentially inappropriate based
exclusively on age ≥65 years. Furthermore, the panel con-
vened by Zhan et al. concluded that drugs such as
amitriptyline "are often misused in clinical practice" [13].
Finally, we note that the database was limited to informa-
tion from encounters with GPs. Patients who were seen
for the treatment of GAD by psychiatrists may not have
been included in our study (unless they also received a
diagnosis of GAD from their GPs). Moreover, all informa-
tion on prescription drugs is limited to those that are dis-
pensed by GPs. The generalizability of our findings to all
older patients with GAD is therefore unknown.
Conclusion
GPs in Germany often prescribe medications that have
been designated as potentially inappropriate to their eld-
erly patients with GAD – especially those with comorbid
depressive disorders. Further research is needed to ascer-
tain whether there are specific subgoups of elderly
patients with GAD for whom the benefits of these medi-
cations outweigh their risks.
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